Patients with hereditary angioedema experienced improved symptom control, quality of life, and treatment satisfaction when using deucrictibant, an orally administered bradykinin B2 receptor antagonist, in a study presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting. The study enrolled patients aged 18 to 75 with type 1 or 2 HAE who were not receiving other prophylactic treatments. Results showed that 90% of the treatment groups achieved control by 12 weeks, with quality of life scores improving by 25.9 points. The researchers plan to continue studying deucrictibant in phase 3 trials to further understand its potential benefits for patients with HAE.
Source link
Hereditary angioedema controlled in 4 weeks with deucrictibant
